Careers Media center Contacts

Taclor from Arterium: first domestic drug with chlorthalidone molecule

Taclor from Arterium: first domestic drug with chlorthalidone molecule

6 April 2021 | News

The cardiac portfolio of Arterium’s drugs has been supplemented with a new product – Taclor. The drug is used in hypertension treatment. The product belongs to thiazide-like diuretics and is the first domestic mono preparation of chlorthalidone. Thiazide and thiazide-like diuretics are first-line drugs for the treatment of hypertension. Thiazide-like diuretics, in contrast to thiazides, are more effective in reducing the risk of heart attacks, strokes and heart failure. 

 

The chlorthalidone molecule is part of international protocols for the treatment of patients with hypertension and has a strong evidence base. This molecule, unlike other thiazide and thiazide-like diuretics, acts for up to 72 hours. It has not only a diuretic effect but also a direct vasodilating effect. Due to this, Taclor has a pronounced antihypertensive effect and provides stable pressure control. 

 

The American Heart Association recommends chlorthalidone to patients with resistant hypertension. Hypertension is resistant if the patient takes three or more antihypertensive drugs of different classes in adequate doses and does not achieve blood pressure control. Such patients are advised to increase diuretic therapy, as fluid retention may be the cause of resistance.

Media gallery
PRESS KIT

Here you can find general information about the company intended for journalists and other stakeholders

MEDIA CONTACTS

For all media-related enquiries,
please contact us
e-mail: pr@arterium.ua
mob.: +38050 446 71 20, +38095 278 92 80